Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)

NCT04844099 is registered in ClinicalTrials.gov with Liverpool School of Tropical Medicine as lead sponsor.

NCT NCT04844099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04844099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)
Lead sponsor
Liverpool School of Tropical Medicine
Phase
Phase 3
Overall status
Completed
Start date
April 9, 2021
Completion date
July 12, 2023
Enrollment
723 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, sickle cell anemia in children